NCT04737330 - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

May 16, 2023

Study Completion Date

May 16, 2023

Conditions

Thyroid Eye DiseaseGraves Orbitopathy

Interventions

DRUG

Secukinumab

Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12

DRUG

Placebo

Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12

Trial Locations (5)

Novartis Investigative Site, Göttingen

Novartis Investigative Site, Essen

Novartis Investigative Site, Mainz

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Freiburg im Breisgau